MarketPulse
S

$SNGX

4 articles found
4 positive
0 negative
0 neutral
BenzingaBenzinga··Soligenix, Inc.

Soligenix's HyBryte Shows Promise Against Cutaneous Lymphoma at 2026 Workshop

Soligenix's HyBryte™ cutaneous lymphoma therapy shows positive results ahead of 2026 presentation, with FDA awarding $2.6M development grant.
SNGXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Ibn

Soligenix Reports Promising 48% Response Rate in HyBryte Phase 3 Study

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.
SNGXPhase 3 clinical trialbiotech
BenzingaBenzinga··Prnewswire

Soligenix's SGX945 Earns UK Innovative Medicine Designation for Behçet's Disease

Soligenix's SGX945 earns UK Promising Innovative Medicine designation for Behçet's Disease, enabling early patient access with Phase 2 data showing 40% ulcer improvement.
SNGXrare diseaseBehçet's Disease
BenzingaBenzinga··Prnewswire

Soligenix Wins EMA Backing for SGX945 Orphan Drug Status in Behçet's Disease

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.
SNGXrare diseaseclinical trial